$CELC SEC Filings

Filed On	Filing
09 Oct 2026	Form 4: Furcht Leo, Director Received 250 shares by exercise or conversion ($1.9K)
05 Oct 2026	Form 4: Gryska David W, Director Received 893 shares as a grant or award
05 Oct 2026	Form 3: Gryska David W, Director No securities owned
02 Oct 2026	8-K: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Regulation FD Disclosure Mr. Gryska brings decades of strategic and financial leadership experience to Celcuity’s Board
30 Sep 2026	8-K: Regulation FD Disclosure; Other Events REVTORPYK is indicated for patients with HR+/HER2- advanced breast cancer without a PIK3CA mutation detected following progression on or after at least one line of endocrine therapy in the metastatic setting
26 Aug 2026	8-K: Regulation FD Disclosure; Other Events
18 Aug 2026	Form 4: Laing Lance G., Director Received 20,000 shares as a grant or award · Granted 10,000 Performance Stock Units
18 Aug 2026	Form 4: Sullivan Brian F., Director Received 80,000 shares as a grant or award · Granted 120,000 Performance Stock Units
18 Aug 2026	Form 4: Hahne Vicky, Chief Financial Officer Received 16,000 shares as a grant or award · Granted 10,000 Performance Stock Units
13 Aug 2026	10-Q
13 Aug 2026	8-K: Results of Operations and Financial Condition
11 Aug 2026	SCHEDULE 13G
16 Jul 2026	SCHEDULE 13G
16 Jul 2026	SCHEDULE 13D/A
16 Jul 2026	Form 4: Baker Bros. Advisors Lp, Former 10% owner and 3 others Sold 3,100,000 shares ($318M)
15 Jul 2026	8-K/A: Regulation FD Disclosure; Other Events Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer
15 Jul 2026	8-K: Regulation FD Disclosure; Other Events
14 Jul 2026	144
14 Jul 2026	144
12 Jun 2026	Form 4: Murphy Polly A., Director Gave 14,048 Stock Option (right to buy) as a gift · Acquired 14,048 Stock Option (right to buy) (Gift)

Comments